International Urogynecology Journal

, Volume 17, Issue 6, pp 636–641 | Cite as

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

  • R. M. Freeman
  • O. Adekanmi
  • M. R. Waterfield
  • A. E. Waterfield
  • D. Wright
  • J. Zajicek
Original Article

Abstract

Objective: To test whether cannabinoids reduce urge incontinence episodes without affecting voiding in patients with multiple sclerosis. This was part of the multicentre trial of the Cannabinoids in Multiple Sclerosis (CAMS) study. Subjects and methods: The CAMS study randomised 630 patients to receive oral administration of cannabis extract, Δ9-tetrahydrocannabinol (THC) or matched placebo. For this substudy subjects completed incontinence diaries. Results: All three groups showed a significant reduction, p<0.01, in adjusted episode rate (i.e. correcting for baseline imbalance) from baseline to the end of treatment: cannabis extract, 38%; THC, 33%; and placebo, 18%. Both active treatments showed significant effects over placebo (cannabis extract, p=0.005; THC, p=0.039). Conclusion: The findings are suggestive of a clinical effect of cannabis on incontinence episodes in patients with MS. This is in contrast to the negative finding of the CAMS study, where no difference was seen in the primary outcome of spasticity.

Keywords

Cannabis Cannabinoid Multiple sclerosis Urge incontinence Neurogenic detrusor overactivity Controlled trial 

References

  1. 1.
    Betts CD, Dmellow MT, Fowler CJ (1993) Urinary symptoms and the neurological features of bladder dysfunction in multiple-sclerosis. J Neurol Neurosurg Psychiatry 56(3):245–250PubMedGoogle Scholar
  2. 2.
    Goldstein I, Siroky MB, Sax DS, Krane RJ (1982) Neurourologic abnormalities in multiple-sclerosis. J Urol 128(3):541–545PubMedGoogle Scholar
  3. 3.
    Hinson JL, Boone TB (1996) Urodynamics and multiple sclerosis. Urol Clin North Am 23(3):475PubMedCrossRefGoogle Scholar
  4. 4.
    Sliwa JA, Bell HK, Mason KD, Gore RM, Nanninga J, Cohen B (1996) Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Arch Phys Med Rehabil 77(3):247–251PubMedCrossRefGoogle Scholar
  5. 5.
    Nathan PW, Smith NC (1982) The centrifugal pathway for micturition with the spinal cord. J Neurol Neurosurg Psychiatry 21:177CrossRefGoogle Scholar
  6. 6.
    Chancellor MB, Blaivas JG (1994) Urological and sexual problems in multiple-sclerosis. Clin Neurosci 2(3–4):189–195PubMedGoogle Scholar
  7. 7.
    Gonor SE, Carroll DJ, Metcalfe JB (1985) Vesical dysfunction in multiple-sclerosis. Urology 25(4):429–431PubMedCrossRefGoogle Scholar
  8. 8.
    Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A (2002) Conservative management in neuropathic urinary incontinence. In: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754Google Scholar
  9. 9.
    De Ridder D, Baert L (2000) Vanilloids and the overactive bladder. BJU Int 86(2):172–180PubMedCrossRefGoogle Scholar
  10. 10.
    de Seze M, Wiart L, Ferriere JM, de Seze MP, Joseph PA, Barat M (1999) Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 36(4):267–277PubMedCrossRefGoogle Scholar
  11. 11.
    Rapp DE, Lucioni A, Katz EE, O’Connor RC, Gerber GS, Bales GT (2004) Use of botulinum-a toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63:1071–1075PubMedCrossRefGoogle Scholar
  12. 12.
    Litwiller SE, Frohman EM, Zimmern PE (1999) Multiple sclerosis and the urologist. J Urol 161(3):743–757PubMedCrossRefGoogle Scholar
  13. 13.
    Burton TA (1979) Urinary retention following cannabis ingestion. JAMA 242(4):351PubMedCrossRefGoogle Scholar
  14. 14.
    Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48PubMedGoogle Scholar
  15. 15.
    Brady CM, DasGupta R, Wiseman OJ, Dalton CM, Berkley KJ, Fowler CJ (2002) The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J Neurol Neurosurg Psychiatry 72(1):139Google Scholar
  16. 16.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362(9395):1517–1526PubMedCrossRefGoogle Scholar
  17. 17.
    Groutz A, Blaivas JG, Chaikin DC, Resnick NM, Engleman K, Anzalone D, Bryzinski B, Wein AJ (2000) Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. J Urol 164(3):698–701PubMedCrossRefGoogle Scholar
  18. 18.
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104(12):1374–1379PubMedGoogle Scholar
  19. 19.
    Lose G, Fantl JA, Victor A, Walter S, Wells TL, Wyman J, Mattiasson A (1998) Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction. Neurourol Urodyn 17(3):255–262PubMedCrossRefGoogle Scholar
  20. 20.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the of the International Standardisation Sub-Committee Continence Society. Neurourol Urodyn 21(2):167–178PubMedCrossRefGoogle Scholar
  21. 21.
    Artibani W, Andersen JT, Gajewski JB, Ostergard DR, Raz S, Tubaro A (2002) Imaging and other investigations. in: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754Google Scholar
  22. 22.
    Goldstein H (1995) Multilevel statistical models, 2nd edn. Arnold, LondonGoogle Scholar
  23. 23.
    Cnaan A, Laird NM, Slasor P (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16(20):2349–2380PubMedCrossRefGoogle Scholar
  24. 24.
    Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849–855PubMedCrossRefGoogle Scholar
  25. 25.
    Greenland JE, Brading A (1995) The in-vitro effect of delta-9 tetrahydrocannabinol on the detrusor smooth muscle of the pig. Proceedings of the International Continence Society, Sydney, pp 87–88Google Scholar
  26. 26.
    Ost D, Van der Aa F, De Ridder D (2001) Immunohistochemical study of the cannabinoid receptors CB1 and CB2 in the human bladder. Mult Scler 7(1):S24Google Scholar
  27. 27.
    Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118(8):2053–2058PubMedGoogle Scholar
  28. 28.
    Blyweert W, Van der Aa F, De Ridder D (2003) Cannabinoid therapy in detrusor overactivity: local versus systemic effect in a spinalised rat model. Neurourol Urodyn 22(5):379–380Google Scholar
  29. 29.
    Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155(3):1023–1029PubMedCrossRefGoogle Scholar

Copyright information

© International Urogynecology Journal 2006

Authors and Affiliations

  • R. M. Freeman
    • 1
  • O. Adekanmi
    • 1
  • M. R. Waterfield
    • 3
  • A. E. Waterfield
    • 1
  • D. Wright
    • 2
  • J. Zajicek
    • 3
  1. 1.Urogynaecology UnitDerriford HospitalPlymouthUK
  2. 2.Department of StatisticsUniversity of PlymouthPlymouthUK
  3. 3.Peninsula Medical SchoolUniversities of Plymouth and ExeterPlymouthUK

Personalised recommendations